Fuji PharmaFuji Pharma Co.,Ltd.4554東証プライム医薬品FY ending Sep 2025, consolidated, J-GAAP

Fuji Pharma FY ending Sep 2020 results

Fuji Pharma brought in ¥33.8B in revenue.

Out of every ¥100 of sales, about ¥9 is left as operating profit.

Revenue changed -6.9% from the prior year, operating profit -24.8%.

Revenue and profit pattern

Revenue and profit down

Revenue -6.9% · profit -24.8%, calculated from disclosed figures.

Operating leverage: 3.62× (profit growth ÷ revenue growth)

FY ending Sep 2019 → FY ending Sep 2020

FY ending Sep 2019 → FY ending Sep 2020

For every ¥100 Fuji Pharma sells, how much goes where, and how much is kept.

FY ending Sep 2020

Gross margin44.0%

Operating margin9.3%

Net margin6.2%

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Show source documents (5)

EDINET (FSA Japan)
有価証券報告書－第60期(2023/10/01－2024/09/30)
ID S100UZR22024-12-23Open
EDINET (FSA Japan)
有価証券報告書－第59期(2022/10/01－2023/09/30)
ID S100SI942023-12-21Open
EDINET (FSA Japan)
有価証券報告書－第58期(令和3年10月1日－令和4年9月30日)
ID S100PTQF2022-12-21Open
EDINET (FSA Japan)
有価証券報告書－第57期(令和2年10月1日－令和3年9月30日)
ID S100N2LZ2021-12-20Open
EDINET (FSA Japan)
有価証券報告書－第56期(令和1年10月1日－令和2年9月30日)
ID S100KDTI2020-12-18Open

Extracted from XBRL: 55 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.